Introduction

One of the most debated questions in regulatory affairs today is whether equivalence is still a viable strategy under EU MDR.

Some say equivalence is effectively dead.

Others argue it remains possible, but only under far stricter conditions.

The truth lies somewhere in between.

Equivalence is not dead. But it is no longer the shortcut it may once have been perceived to be.

Under MDR, equivalence still exists as a regulatory concept. However, the expectations for demonstrating it have increased significantly, and many manufacturers are finding that what worked under older frameworks does not necessarily work now.

What Changed Under MDR?

Under previous European directives, equivalence was often used to support clinical evaluation by leveraging data from another device considered similar.

In practice, some manufacturers relied heavily on literature and comparator devices to bridge gaps in their own clinical evidence.

Under EU MDR, that approach faces much greater scrutiny.

Regulators and Notified Bodies now expect deeper, more defensible evidence that equivalence has truly been established.

This is largely because MDR places stronger emphasis on:

• Clinical evidence quality
• Scientific validity
• Patient safety
• Benefit-risk justification
• Transparency in supporting documentation

The result is a much higher evidentiary bar.

What Does Equivalence Actually Require?

Demonstrating equivalence is not simply showing two devices look similar or have a comparable intended purpose.

A robust equivalence strategy generally requires demonstrating alignment across three areas:

1. Technical Characteristics

This includes whether the devices are comparable in terms of:

• Design
• Specifications
• Materials
• Operating principles
• Performance characteristics

Even small differences can raise questions.

2. Biological Characteristics

This addresses whether the devices:

• Use the same materials
• Have similar tissue contact
• Present comparable biological risks

Differences in materials or processing can undermine equivalence claims.

3. Clinical Characteristics

This includes whether the devices have:

• The same intended purpose
• Similar indications
• Comparable patient populations
• Similar clinical performance expectations

This is often where the greatest scrutiny occurs.

Why Many Equivalence Claims Fail

Many failed submissions do not prove equivalence is impossible.

They often prove that equivalence was not demonstrated rigorously enough.

Common reasons for failure include:

Superficial Comparisons

Claiming devices are “similar” without detailed analysis is rarely sufficient.

Regulators expect evidence, not assumptions.

Insufficient Access to Comparator Data

This is a major challenge.

To prove equivalence, manufacturers often need deep information about the comparator device.

That information may not always be available.

Without it, justification becomes difficult.

Overreliance on Literature

Literature alone often cannot fill significant evidence gaps.

It may support an argument, but rarely replaces a comprehensive equivalence demonstration.

Ignoring Material or Design Differences

Even minor changes may have clinical or biological implications.

These differences must be addressed, not overlooked.

So Is Equivalence Still Possible?

Yes.

But only when it is approached strategically.

Equivalence may still be viable when:

• Devices are genuinely highly comparable
• Strong technical, biological, and clinical data exist
• Access to relevant supporting information is available
• The justification is structured and scientifically robust

In these circumstances, equivalence can still support a clinical evidence strategy.

But it demands far more than it once did.

The Biggest Misconception About Equivalence

The biggest misconception is that equivalence failed because regulators eliminated it.

That is not what happened.

What changed is the tolerance for weak justification.

In many cases, equivalence did not disappear.

Poorly supported equivalence claims simply stopped surviving scrutiny.

That is an important distinction.

When Equivalence May Be Difficult

There are situations where equivalence becomes much harder, particularly for:

• Higher-risk devices
• Novel technologies
• Devices with significant design differences
• Cases where comparator data is inaccessible

In these situations, relying solely on equivalence may be risky.

A stronger strategy may require generating additional clinical evidence.

Equivalence Should Be a Strategy, Not a Default

This is perhaps the most important mindset shift.

Too often, equivalence is treated as the starting point.

It should not be.

It should be considered a strategic option only when the evidence supports it.

The better question is not:

Can we use equivalence?

It is:

Can we defend equivalence under scrutiny?

That changes how manufacturers approach the problem.

How to Make Equivalence More Defensible

If pursuing equivalence under MDR, several principles matter:

Start with Gap Analysis

Identify where comparability is strong—and where it is weak.

Do not assume alignment.

Test it.

Document Comparisons in Depth

Technical, biological, and clinical comparisons must be detailed, not high level.

Depth matters.

Address Differences Directly

Differences should not be hidden.

They should be analyzed and justified.

Integrate Risk Management

Equivalence should align with the broader risk management and clinical evaluation strategy.

It cannot exist in isolation.

Be Realistic

If equivalence is weak, forcing the strategy may create greater regulatory risk than pursuing additional evidence.

What Manufacturers Should Stop Doing

Manufacturers should stop treating equivalence as:

• A shortcut to avoid clinical evidence generation
• A literature exercise
• A documentation formality
• A legacy strategy that still works unchanged under MDR

That thinking creates risk.

Final Thought

So, is equivalence under MDR dead?

No.

But it has evolved.

It is no longer a convenient pathway built on broad similarity claims.

It is a high-scrutiny strategy that requires strong evidence, deep analysis, and defensible justification.

And that changes everything.

The real question is not whether equivalence still exists.

It does.

The real question is whether manufacturers are prepared to meet the standard required to make it work.

Because under EU MDR, equivalence is not dead.

But weak equivalence arguments probably are.